---
title: "Morning Trend | GENSCRIPT BIO's oversold rebound space is limited, can the pharmaceutical theme rise again?"
description: "GENSCRIPT BIO (1548.HK) has recently seen a resurgence in its downward trend, with the daily MACD showing a death cross and a significant expansion of green bars, indicating a clear bearish trend in t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273673008.md"
published_at: "2026-01-27T01:00:00.000Z"
---

# Morning Trend | GENSCRIPT BIO's oversold rebound space is limited, can the pharmaceutical theme rise again?

> GENSCRIPT BIO (1548.HK) has recently seen a resurgence in its downward trend, with the daily MACD showing a death cross and a significant expansion of green bars, indicating a clear bearish trend in technical terms. The market shows a continuous decline in volume, with noticeable capital outflow and a strong wait-and-see sentiment among major players. Although there were signs of an oversold rebound yesterday, the trading volume failed to effectively increase, raising doubts about the sustainability of the rebound. The pharmaceutical sector has performed poorly overall recently, with investors' risk appetite declining, making it difficult for short-term thematic market momentum to emerge. 

On the fundamental side, GENSCRIPT BIO is at the forefront of innovative drug research and development, possessing medium to long-term growth potential. However, it is under pressure from industry regulations and price reductions due to centralized procurement, which has impacted profit growth expectations. Market funds tend to favor short-term risk aversion, and the sector as a whole lacks a systematic basis for upward movement. In the short term, without new clinical progress or significant cooperation news, it is challenging to reverse the weak market trend. 

Technically, the current stock price is near historical support levels, and close attention should be paid to the loss or gain of this support, as a breach could trigger accelerated declines. 

In terms of operational advice, short-term traders should closely monitor the flow of funds and trading activity in the market, and it is not advisable to blindly bottom-fish without accompanying volume. Conservative investors may wait for signs of stabilization in the sector and improvement in the company's fundamentals before entering the market. Pharmaceutical stocks may continue to be in a bottoming phase in the short term, with a focus on defensive holding and effective risk management. Future attention should be paid to the marginal changes in industry policies and their impact on the sector

GENSCRIPT BIO (1548.HK) has recently seen a resurgence in its downward trend, with the daily MACD showing a death cross and a significant expansion of green bars, indicating a clear bearish trend in technical terms. The market shows a continuous decline in volume, with noticeable capital outflow and a strong wait-and-see sentiment among major players. Although there were signs of an oversold rebound yesterday, the trading volume failed to expand effectively, raising doubts about the sustainability of the rebound. The pharmaceutical sector has performed poorly overall recently, with investors' risk appetite declining, making it difficult for short-term thematic market momentum to emerge.

On the fundamental side, GENSCRIPT BIO is at the forefront of innovative drug research and development, possessing medium to long-term growth potential. However, it is under pressure from industry regulation and price reductions due to centralized procurement, which has impacted profit growth expectations. Market funds are leaning towards short-term risk aversion, and the sector as a whole lacks a systematic basis for upward movement. In the short term, without new clinical progress or significant cooperation news, it is challenging to reverse the weak market trend. Technically, the current stock price is near historical support zones, and close attention should be paid to the loss or gain of support, as a breach could trigger accelerated declines.

In terms of operational advice, short-term traders should closely monitor capital flow and trading activity in the market, and it is not advisable to blindly bottom-fish without accompanying volume. Conservative investors may wait for signs of stabilization in the sector and improvement in the company's fundamentals before entering the market. Pharmaceutical stocks may continue to be in a bottoming phase in the short term, and holding positions should focus on defense while managing risks. Future attention should be paid to the marginal changes in industry policies and their impact on the sector

### Related Stocks

- [01548.HK - GENSCRIPT BIO](https://longbridge.com/en/quote/01548.HK.md)
- [LEGN.US - Legend Biotech](https://longbridge.com/en/quote/LEGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 擁 100 萬資金買股好過買樓 關焯照看好銀行及地產股 15% 押注一隻 AI 股｜百萬倉 | 財經名家關焯照建議，若有 100 萬元，選擇買股票而非樓市。他看好本地地產股如恆地和長實，認為即使減派息，股息率仍可達 5 釐多。銀行股方面，推薦渣打，認為其上升空間優於滙豐。對於美股，關焯照看好光通訊和存儲晶片股，認為是科技巨頭投資的受益 | [Link](https://longbridge.com/en/news/276544696.md) |
| 樓市強勁反彈仍受質疑 正是見底訊號「人人看好才是最危險」｜李聲揚 | 樓市近期反彈引發質疑，儘管過去一年樓價走勢良好，買家信心回升。中原城市領先指數 CCL 最新報 149.4 點，單周上升 1.5%，為三年來最大單周升幅。市場對樓市的未來走勢仍存疑慮，歷史經驗顯示此時可能是樓市見底的信號。儘管樓價仍距歷史高 | [Link](https://longbridge.com/en/news/276522533.md) |
| 發展黃金市場為今年重頭戲 許正宇：逾十銀行加入港金結算公司理事會 | 香港財經事務及庫務局局長許正宇表示，發展黃金市場是今年的重點，已與上海黃金交易所籤署合作協議，成立港金結算公司，預計年內啟動運作。超過 10 家銀行已確認加入理事會，目標是開發香港的黃金中央清算系統。此外，香港新股市場活躍，但對新股質素的關 | [Link](https://longbridge.com/en/news/276291952.md) |
| 數字黃金、未來支付、投機之選？比特幣的 “敍事” 在 “信仰巔峯” 逐個崩塌 | 賦予比特幣引力的故事——數字黃金、自由貨幣、投機功能正在同時瓦解，代幣化、區塊鏈驅動的衍生品和跨境穩定幣支付正在成為可信的用例，而這些都不需要比特幣參與。同時，黃金和白銀今年上演了波動性反彈，而加密貨幣只是下跌。此外，比特幣對投機文化的掌控 | [Link](https://longbridge.com/en/news/276523166.md) |
| 早盤趨勢點評｜恆隆地產（101.HK）量能回升，地產板塊復甦跡象初現 | 昨日恆隆地產尾盤持續放量，伴隨行業政策與需求端雙重利好，地產板塊出現右側反彈。龍頭企業獲長線資金關注，主力在關鍵均線位連續買入。 技術方面，日內 K 線陽包陰，成交增量配合到位，MACD 紅柱轉強，短期均線形成支撐。市場博弈情緒改善，整體信 | [Link](https://longbridge.com/en/news/275099596.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.